Current status and progress of lymphoma management in China

Abstract

Lymphoma is a large group of lymphoid hematopoietic malignancies including Hodgkin lymphoma and non-Hodgkin's lymphoma. The various subtypes of lymphoma are different in clinical features, response to treatment and prognoses. The relative frequency of specific subtypes of lymphoma varies geographically. The mature T cell lymphoma is much more common in East Asia compared with Western countries. Chemotherapy plays an important role in the treatment of lymphoma. With advances in understanding the biology and genetics of lymphoma, many new agents are used in the treatment of lymphoma. In mainland China, some new agents and new combination chemotherapy regimens showed high efficacy and good tolerability. Chidamide, a histone deacetylase inhibitor, has been approved for the treatment of relapsed or refractory peripheral T cell lymphoma by the China Food and Drug Administration. Anti-programmed death 1 antibodies and chimeric antigen receptor-engineered T cells have been explored for lymphoma immunotherapy in Chinese patients. Advances in the treatment have substantially increased the likelihood of cure for patients with lymphoma.

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

“…The pivotal PROPEL study, which was conducted in predominantly White patients recruited in the USA, Canada, and Europe, reported an ORR of 29%, while an ORR of 45% was observed in the Phase I/II study of Japanese patients [ 21 , 22 ]. The reason for these differing outcomes may relate in part to differences in the patient populations, including fewer prior treatments in the present study (median [range] 2 [1–14]) compared with PROPEL (3 [ 1 – 13 ]) and the Japanese Phase I/II study (3 [ 1 – 8 ]) and PTCL subtype distribution [ 21 , 22 ]. While higher response rates were observed in patients with ALK-negative ALCL (83%, n = 6 [all ALCL 75%, n = 8]) and AITL (55%, n = 20) in the present study compared with PROPEL (all ALCL 35% [ n = 17]; AITL 8% [ n = 13]) and the Phase I/II Japanese study (ALK-negative ALCL 50% [ n = 2]; AITL 44% [ n = 9]), small patient numbers limit the interpretation of these findings.…”

“…Brentuximab vedotin was also recently approved with chemotherapy for first-line CD30 + PTCL following data from the ECHELON-2 Phase III trial [ 11 ]. However, most patients are either refractory to initial therapy or relapse despite consolidative autologous stem cell transplantation [ 12 , 13 ]. At present, treatment options are limited for many patients with relapsed/refractory PTCL, and a median OS of just 6 months is reported following relapse or progression in patients treated with chemotherapy [ 14 ].…”

The Antitumor Activities of Marsdenia tenacissima

“…Lymphoma is a large group of lymphoid hematopoietic malignancies including Hodgkin's lymphoma and non-Hodgkin's lymphoma. With advances in understanding the biology and genetics of lymphoma, many new agents, including natural agents, are being used in the treatment of lymphoma ( 48 ). According to the studies, vascular endothelial growth factor (VEGF) is one of the most effective and specific facilitators of angiogenesis and it forms new blood vessels by stimulating endothelial cell (EC) proliferation.…”

Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis

“…Peripheral T-cell lymphoma (PTCL) is a rare disease, comprising only 5-10% of all lymphoid neoplasms [1], but it shows a higher prevalence in China (23-27%) [2]. As a biologically and clinically heterogeneous group of diseases, PTCL remains a therapeutic challenge.…”